934 related articles for article (PubMed ID: 17592266)
1. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
4. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
5. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of papillary tubal hyperplasia associated with ovarian atypical proliferative serous tumor and low-grade serous carcinoma.
Huang WC; Tsai CC; Wei MC; Kuo KT
Am J Obstet Gynecol; 2013 Aug; 209(2):e6-8. PubMed ID: 23711666
[TBL] [Abstract][Full Text] [Related]
7. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
11. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
14. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
15. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
16. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion.
Yemelyanova A; Mao TL; Nakayama N; Shih IeM; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1800-6. PubMed ID: 18779727
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
18. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
Shih IeM; Kurman RJ
Am J Pathol; 2004 May; 164(5):1511-8. PubMed ID: 15111296
[TBL] [Abstract][Full Text] [Related]
19. Origins and molecular pathology of ovarian cancer.
Bell DA
Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
[TBL] [Abstract][Full Text] [Related]
20. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]